ambroxol ?

[CV119]

Anyone familiar with this drug and their benefits for parkinson's? Found two studies, but not sure if it became mainstream and readily available?

[MarkPrana]

Some recent discussions here:

healthunlocked.com/cure-par...

[ParkinsonsLady]

There is presently a clinical trial going on with it at multiple sites in the United Kingdom.

[PHILCAM]

Ambroxol hydrochloride, commonly used as a cough medicine, has shown promise as a potential treatment for Parkinson's Disease (PD). Here's a summary of how it works and its potential benefits:

Mechanism of Action

Alpha-synuclein Accumulation: PD is characterized by the accumulation of alpha-synuclein protein in the brain, forming Lewy bodies that disrupt neurotransmitter signaling and lead to the death of dopaminergic neurons.

Glucocerebrosidase (GCase): Ambroxol acts as a molecular chaperone for the enzyme glucocerebrosidase (GCase). By binding to mutant GCase, Ambroxol increases its activity, which helps reduce the accumulation of alpha-synuclein.

Clinical Studies

Safety and Tolerability: Clinical trials have shown that Ambroxol is safe and well-tolerated in patients with PD.

Crossing the Blood-Brain Barrier: Ambroxol has been shown to cross the blood-brain barrier, allowing it to reach the central nervous system and exert its effects.

Potential Benefits: By enhancing GCase activity, Ambroxol may help reduce the formation of Lewy bodies and slow the progression of PD.

Current Research

Proof-of-Concept Studies: Initial studies have demonstrated that Ambroxol can improve GCase function and reduce alpha-synuclein levels in the spinal fluid of PD patients.

Further Investigation: Larger, placebo-controlled trials are needed to confirm these findings and determine the long-term efficacy of Ambroxol as a treatment for PD.

Ambroxol's potential as a repurposed treatment for PD is an exciting development, and ongoing research will help clarify its role in managing this neurodegenerative disease.

parkinson.org/blog/science-...

[PHILCAM in reply to PHILCAM]

In a study published in JAMA Neurology, participants took progressively increasing doses of Ambroxol over a 186-day period. The dosage started at 60 mg per day and was gradually increased to 1,260 mg per day - - - very high doses

The study found that Ambroxol was safe and well-tolerated at these doses, and it successfully crossed the blood-brain barrier.

jamanetwork.com/journals/ja...

[AkunaMatata]

Phase 3 trial started last month: isrctn.com/ISRCTN93097821